Combination therapy of malononitrilamides and tacrolimus (FK 506) induced long-term xenograft survival.
Schorlemmer
H U
HU
Research Laboratories Hoechst Marion Roussel Deutschland GmbH, Wiesbaden, Germany.
Kurrle
R
R
D020106:Acrylamide / Q000627:therapeutic use; D000178:Acrylamides; D000284:Administration, Oral; D000480:Alkynes; D000818:Animals; D002208:Caproates / Q000627:therapeutic use*; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D006085:Graft Survival / Q000187:drug effects* / Q000276:immunology; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D007555:Isoxazoles; D051379:Mice; D008807:Mice, Inbred BALB C; D009570:Nitriles; D051381:Rats; D011917:Rats, Inbred Lew; D016038:Skin Transplantation / Q000276:immunology*; D016559:Tacrolimus / Q000627:therapeutic use*; D013997:Time Factors; D014183:Transplantation, Heterologous / Q000276:immunology*
D000178:Acrylamides; D000480:Alkynes; D002208:Caproates; D007166:Immunosuppressive Agents; D007555:Isoxazoles; D009570:Nitriles; C115284:2-cyano-3-hydroxy-N-(4-(trifluoromethyl)phenyl)-2-hepten-6-ynamide; D020106:Acrylamide; C116406:HMR 1279; D016559:Tacrolimus